Editor’s note. This issue covers September 30 – October 19, 2026, plus late-September FDA approvals carried forward (a three-week recovery issue). Record cutoff: October 19, 2026, 4:00 PM PT. Once published, this issue is never edited except through a dated correction note.
1. Five things that matter
- Medicare Advantage directories become a measured obligation (proposed). CMS-4214-P would require 90-day verification, an annual accuracy score shown to enrollees as a letter grade from 2029, and in-network cost sharing for enrollees who relied on a wrong listing. It starts in 2028. Comments are due Dec 15.
- AI scribes cross the device line. Australia's TGA found 8 of the 12 scribes it examined likely contain medical-device functions; none of their suppliers said so. FDA's generative-AI comment window closed Oct 19, and the UK's MHRA published a 2030 strategy that includes a modern framework for AI as a medical device (as reported; primary not yet read).
- One entry point for criminal health-care fraud disclosures. As of Oct 15, a qualifying disclosure to DOJ's Fraud Division also receives the benefits of HHS-OIG's Self-Disclosure Protocol. There is no immunity and no shelter from mandatory exclusion.
- Medi-Cal changes how two million members reach care on Jan 1. Members with unsatisfactory immigration status move to Fee-for-Service. Thousands of providers who serve them are not yet enrolled to bill it.
- An organ-sparing option in rectal cancer, for a small biomarker group. Dostarlimab received accelerated approval for dMMR/MSI-H locally advanced disease.
2. What changed (newest first)
| Date | Development | Status |
|---|---|---|
| Oct 19 | Dostarlimab accelerated approval, dMMR/MSI-H Stage II/III rectal cancer | Approved — accelerated |
| Oct 19 | FDA generative-AI device discussion paper: comments close | Comment period closed; no guidance |
| Oct 19 | CA AG $6M settlement with Chrome Holding (formerly 23andMe) | Civil settlement, pending court approval |
| Oct 16 | CMS-4214-P (MA directories, PBM fees, LIS cost sharing) | Proposed |
| Oct 16 | TGA digital-scribe review outcomes | Review findings |
| Oct 16 | WHO AFRO: Kenya 3 confirmed Bundibugyo cases | Active outbreak |
| Oct 15 | DOJ–HHS-OIG self-disclosure coordination policy | Final enforcement policy |
| Oct 15 | MHRA antidepressant safety information | Safety communication; 2027 leaflet |
| Oct 15 | EMA CHMP: six new medicines recommended | Opinion — EC decision pending |
| Oct 14 | FDA Rare Disease Framework Initiative | Request for information |
| Oct 14 | Anktiva expanded to BCG-unresponsive papillary-only NMIBC | Supplemental approval |
| Oct 14 | MHRA seizure of >12,000 suspected counterfeit GLP-1 pens | Seizure / investigation |
| Oct 13 | CVS $315M opioid-dispensing settlement | Civil settlement |
| Oct 12 | WHO Pandemic Hub strategy to 2030 | Strategy (target) |
| Oct 12 | Singapore HSA–MHRA corridor; HSA–ACE concurrent review | Announced |
| Oct 8 | 2027 Star Ratings posted | Published |
| Oct 8 | CLIA proposed rule | Proposed; comments to Dec 7 |
| Oct 6 | Transparency in Coverage final rule | Final; phased from Jan 1, 2027 |
| Oct 2 | GLOBE model final rule published (effective Nov 30) | Final |
| Oct 1 | CDRH FY2027 guidance priorities | Agenda |
| Oct 1 | Autus size-adjustable pediatric valve | Approved (PMA) |
| Sept 30 | Independence Blue Cross $22.5M; Signal Diagnostics $20.5M | Civil settlements |
| Sept 28 | Emcitate (MCT8 deficiency) | Approved |
| Sept 23 | Onswik (weekly insulin efsitora, T2D) | Approved |
3. California
- Medi-Cal Fee-for-Service, January 1. The question is not coverage but access. DHCS figures relayed by the CMA show about 20,000 providers serving affected patients who are not enrolled in Fee-for-Service, and enrollment can take up to 90 days. Practices that want continuity for these patients need to apply now.
- Rural Health Transformation. The $233.6 million award is confirmed. The CalRHT council meets Oct 27. The "Oct 30" commitment date is reported but unconfirmed on a primary page.
- Medical Board of California meets Nov 18–20 in Bakersfield. Panel agendas are posted; the full Board agenda is not.
- California enforcement: AHF ($1.44M, MA coding); an E.D. Cal. DME indictment; the AG's contempt motion against Martin Shkreli; the 23andMe/Chrome settlement.
4. United States
- CMS-4214-P (above). Transparency in Coverage restructured (files per network, quarterly; patient tools from Jan 1, 2027). CLIA modernization proposed. The GLOBE model rule published Oct 2, effective Nov 30.
- FDA: the rare-disease framework (Oct 28 meeting); the generative-AI device docket closed; CDRH's FY2027 list, with generative-AI risk and evidence "under construction".
- NPDB: Query consolidation on Dec 4.
5. Global signals
- Ebola (Bundibugyo). DRC: 9,066 confirmed cases and 4,381 deaths across 65 health zones (as of Oct 11). Kenya: 3 confirmed and 1 death, all linked (as of Oct 16). WHO sees no community spread in Kenya. The PHEIC remains in force.
- EU: CHMP backed oral orforglipron (obesity and T2D), daraxonrasib (pancreatic cancer) and navepegritide (achondroplasia). These are opinions only.
- UK: MHRA's 2030 strategy (as reported); antidepressant safety information; the counterfeit-pen seizure.
- Singapore: concurrent regulatory review and HTA through the HSA–ACE Priority Track.
- WHO: the 24-hour detection target for 2030.
6. Clinical frontier
Dostarlimab (dMMR/MSI-H LARC; accelerated). Anktiva papillary-only expansion (extrapolated from the CIS cohort). Autus growing pediatric valve. Emcitate (first therapy for MCT8-deficiency thyrotoxicosis). Onswik (once-weekly basal insulin, T2D only). Hovilpri (refractory HSV in immunocompromised adults). Atezolizumab adjuvant (Stage III dMMR colon). Pirtobrutinib first-line CLL/SLL. Device alert: Edwards SAPIEN M3 Commander M delivery-system lots (Oct 15 Early Alert).
7. Enforcement signals
- 19 years for the HealthSplash/DMERx owner ($1B+ billed).
- 14 years in a $30M DME scheme.
- Convictions in COVID-testing, Medicaid-housing and telehealth-stimulant cases.
- CVS $315M (opioids).
- Two MA risk-adjustment settlements.
- More pandemic-program resolutions (Heal 360 $20M; Signal Diagnostics $20.5M; the Connecticut physician, $866,539 with a 3-year exclusion).
Every civil item is a settlement of allegations, not a finding. See the full ledger.
8. Policy gap of the week
Nobody owns the accuracy of what an AI scribe writes.
- The clinician signs.
- The health system mandates the tool.
- The vendor controls the model and its updates.
When a generated assessment enters the record, nothing in it shows whether the clinician decided it or merely failed to delete it.
9. KPSGILL recommendation
Classify every documentation-AI feature by function: transcription, documentation assistance, clinical inference, downstream action. Attach obligations only where inference begins. Make provenance visible in the signed record: model, version, and which content was machine-inferred.
10. Model policy / implementation architecture
The revised Model AI Medical Record Integrity Standard (Reform) has five elements:
- functional classification;
- visible provenance;
- clinician control with no override penalty;
- change notification and incident reporting;
- procurement accountability.
It is written as a rule for deploying organizations and professional practice, to stay clear of federal device preemption. It is model text, not law.
11. Next week and beyond
Oct 26 (Angelo hearing, as last verified Oct 9); Oct 27 (CalRHT council); Oct 28 (FDA rare-disease meeting); Nov 2 (OHCA rules effective); Nov 18–20 (MBC); Nov 30 (CDRH list comments); Dec 4 (NPDB Query); Dec 7 (open enrollment ends; CLIA comments); Dec 11; Dec 15; Jan 1, 2027.
12. Forecasts issued this week
F-2026-10-19-01 through -06: CMS directory rules; TGA action on scribes; no binding U.S. generative-AI device guidance in 2027; rare-disease framework guidance first; DHCS authorization-carryover guidance; Ebola in Kenya.
13. Prior-forecast review
None of the four forecasts issued Aug 30 has resolved. This week's evidence bears on two, without scoring them:
- "Board cases before board guidance." The TGA's scribe findings increase the likelihood that generated documentation becomes evidence in professional proceedings.
- "Coverage-denial transparency." No new evidence.
14. Three policies KPSGILL would change this week
- Directories. Extend CMS-4214-P from listing accuracy to appointment availability, through a shared provider-attestation source.
- AI scribes. California should adopt function-based provenance and incident-reporting duties for deploying organizations.
- Medi-Cal Fee-for-Service. DHCS should publish its authorization-carryover rule now and fast-track Fee-for-Service enrollment for providers already credentialed in managed care.
15. Documentary ledger
- R01 · FDA grants accelerated approval to dostarlimab for dMMR/MSI-H locally advanced rectal cancer
- R02 · FDA's generative-AI medical-device discussion paper: comment period closes
- R03 · California AG: $6 million settlement with Chrome Holding Co. (formerly 23andMe)
- R04 · CMS proposes Medicare Advantage directory-accuracy, PBM-compensation and low-income cost-sharing rules (CMS-4214-P)
- R05 · DOJ Fraud Division and HHS-OIG coordinate self-disclosure of potentially criminal health-care fraud
- R06 · Rare Disease Framework Initiative launched; public meeting October 28
- R07 · MHRA strengthens antidepressant safety information
- R08 · MHRA and West Midlands Police seize suspected counterfeit tirzepatide and retatrutide pens
- R09 · EMA's CHMP recommends six new medicines, including oral orforglipron
- R10 · Australia's TGA: 8 of 12 digital medical scribes likely contain medical-device functions
- R11 · WHO: Kenya confirms Bundibugyo cases linked to the DRC outbreak; DRC totals as of October 11
- R12 · Singapore HSA: Regulatory Innovation Corridor with MHRA; concurrent regulatory and HTA review
- R13 · WHO Hub for Pandemic and Epidemic Intelligence launches its 2030 strategy
- R14 · CMS finalizes Transparency in Coverage revisions (CMS-9882-F)
- R15 · Medicare Advantage and Part D 2027 Star Ratings published
- R16 · CMS proposes CLIA modernization (CMS-3478-P)
- R17 · CDRH FY2027 guidance priorities posted
- R18 · Edwards SAPIEN M3 Commander M delivery systems: FDA Early Alert
- R19 · NPDB: One-Time Query and Continuous Query merge into "NPDB Query" on December 4
- R20 · Autus Size-Adjustable Valve — first heart valve designed to be expanded as a child grows
- R21 · Emcitate (tiratricol) — first treatment for peripheral thyrotoxicosis in MCT8 deficiency (Allan-Herndon-Dudley syndrome)
- R22 · Onswik (insulin efsitora alfa) — once-weekly basal insulin for adults with type 2 diabetes
- R23 · Other verified FDA approvals in the window: listed under Clinical frontier above.
- Enforcement E01–E23: ledger of September 28 – October 19, 2026, each row with its primary source.